Samsung Bioepis Co., Ltd.

Samsung Bioepis Co. , Ltd. , based in Incheon, South Korea, specializes in the development and commercialization of biosimilars, providing innovative biologic medicines to enhance patient access to effective treatments in oncology and autoimmune diseases. Founded in 2012 in Incheon, South Korea, Samsung Bioepis Co.

, Ltd. focuses on the development of biosimilars tailored to meet rigorous regulatory standards. The company was established as a subsidiary of Samsung Biologics, emphasizing strategic collaboration and operational synergy. The founding team includes seasoned professionals with extensive backgrounds in biotechnology and pharmaceuticals, although specific information about prior companies is not available.

Samsung Bioepis specializes in the development and commercialization of biosimilars, which are biologic medical products highly similar to already approved reference products. Their core offerings are designed to address various medical conditions, particularly in oncology and autoimmune diseases, by providing quality-assured medicines that enhance patient access to effective treatments. The company's products are tailored for healthcare providers, hospitals, and patients, with a focus on meeting stringent regulatory standards across multiple regions including the United States, Europe, and South Korea. Samsung Bioepis aims to solve critical healthcare challenges by delivering affordable alternatives to existing biologics, thereby catering to a diverse client base that includes healthcare professionals and patients who rely on these therapies for chronic and life-threatening conditions.

Samsung Bioepis generates revenue primarily through partnerships and strategic collaborations with pharmaceutical companies for the development, manufacturing, and commercialization of its biosimilars. The business model includes B2B transactions where products are sold to healthcare providers, hospitals, and specialty pharmacies, optimizing distribution channels to ensure accessibility for end-users. Revenue is structured through negotiated agreements that outline terms for product supply and pricing, which may vary based on market dynamics and product-specific considerations. The company’s flagship biosimilar products, designed to compete with established biologics, contribute significantly to its revenue streams as they gain market approval and acceptance in targeted geographical regions.